Status:

TERMINATED

Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons

Lead Sponsor:

Mayo Clinic

Conditions:

Pre-Diabetic

Eligibility:

All Genders

20-45 years

Phase:

PHASE1

Brief Summary

The purpose of this research is to study the effects of 1,25(OH)2 D3 (a prescription form of active Vitamin D) on muscle strength and insulin secretion by the pancreas and glucose utilization by skele...

Eligibility Criteria

Inclusion

  • Body mass index (BMI) of \>24kg/m2
  • Fasting serum glucose \<126 mg/dL

Exclusion

  • BMI\</=24 kg/m2
  • Fasting serum glucose \>/=126 mg/dL
  • Patient is taking Calcium or Vitamin D supplements and is unwilling to stop for 8 weeks
  • Serum Calcium \>10.2 mg/dL
  • Serum inorganic phosphorous \>4.5mg/dL
  • Pregnancy or breastfeeding
  • Diagnosis of Diabetes Mellitus
  • Diagnosis of Rheumatoid Arthritis
  • Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
  • Renal in sufficiency/failure ( serum creatinine \>1.5 mg/dL men, \> 1.3 mg/dL women)
  • Chronic active liver disease (bilirubin \>1.2 mg/dL, AST\>144IU/L, or ALT \>165 IU/L)
  • History of chronic hepatitis
  • Active coronary artery disease ( unstable angina, myocardial infarction, stroke and revascularization of coronary, peripheral or carotid artery within the last 3 months)
  • Oral warfarin group medications or history of blood clotting disorders
  • Platelet count \<100,000 per uL within the last 7 days
  • Alcohol consumption greater than 2 glasses/day or other substance abuse
  • Untreated or uncontrolled thyroid disorders (outside a TSH range of 0.5 to 10mIU/L)
  • Debilitating chronic disease (at the discretion of the investigators)
  • The presence of infections, highly communicable diseases ( AIDS, active tuberculosis, venereal disease, hepatitis)
  • Any malignancy

Key Trial Info

Start Date :

October 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 28 2021

Estimated Enrollment :

17 Patients enrolled

Trial Details

Trial ID

NCT04286529

Start Date

October 1 2020

End Date

May 28 2021

Last Update

April 18 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic

Rochester, Minnesota, United States, 55905